Skip to main content
SpringerLink
Log in

Metastasiertes Lungenkarzinom

Antiangiogenese plus PD-L1-Hemmer in der Erstlinie beim nsqNSCLC erfolgreich

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50

    Article  Google Scholar 

  2. Crinò L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumab- based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–40

    Article  CAS  PubMed  Google Scholar 

Originalie

  • Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin IV, Flemmingstraße 2, 09116, Chemnitz, Deutschland

    Stefan Hammerschmidt

Authors
  1. Stefan Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hammerschmidt, S. Antiangiogenese plus PD-L1-Hemmer in der Erstlinie beim nsqNSCLC erfolgreich. Pneumo News 10, 20–21 (2018). https://doi.org/10.1007/s15033-018-0976-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-018-0976-x

Search

Navigation